Peptonic Medical AB (publ) - Publishes financial report for the first quarter 2026

Key figures for the Group - First quarter (January - March)

• Sales of goods amounted to KSEK 3 138 (3 758).
• Gross profit amounted to KSEK 2 121 (2 165), corresponding to a gross margin of 68 (58) percent.
• Operating profit amounted to KSEK -5 330 (-7 459).
• Earnings per share amounted to SEK -0,0005 (-0,001).

Key figures for the Mother company - First quarter (January - March)

• Sales of goods amounted to KSEK 3 138 (3 302).
• Gross profit amounted to KSEK 2 121 (1 993), corresponding to a gross margin of 68 (58) percent.
• Operating loss amounted to KSEK -5 305 (-7 116)

Significant events

First quarter

29 JAN Announces results of completed rights issue.

12 FEB Decides on a directed new issue of units to underwriters in connection with the completed rights issue

25 FEB Announces termination of liquidity guarantee

26 FEB The board appoints interim CEO

After the end of the period

28 APR Provides an update on the product Vernivia and the ongoing MDR process for updating the CE marking

20 MAY Product launch of VagiVital Intimate V Wipes, intimate wipes

22 MAY Product launch of VagiVital Moisturizing Intimate Cream, a new product in moisturizing intimate care

Comments by the CEO

The first quarter marks an important turning point for Peptonic. After a long and demanding restructuring process, the company is now stronger, more focused and fully focused on the future. The fact that we have successfully gone through this process does not only mean increased stability - it also gives us the right conditions to accelerate development and create long-term shareholder value.

Over the past year, we have implemented extensive changes to streamline operations, streamline the organization and lower the cost base. The result is a significantly more cost-effective company with a clearer structure and better scalability. Today, we have an organization that is better aligned with our strategic goals and that creates a stable foundation for sustainable growth and improved profitability going forward.

Our focus going forward is clear: stronger products, increased sales and continued brand building. The core of Peptonic is our proprietary portfolio in intimate women's health - a segment with strong growth potential and increasing global demand. We see great opportunities to continue to gain market share with our existing products while actively broadening the product portfolio to meet more consumer needs.

An important step in this strategy is the announced launch of two new products under our VagiVital brand, VagiVital Intimate V Wipes and VagiVital Moisturizing Intimate Cream. The launches strengthen our position in intimate care and are part of our ambition to develop VagiVital into a broader and stronger brand with relevance in women's everyday lives. At the same time, we continue to invest in marketing, digital presence and a more diversified sales structure to create scalable and long-term growth.

We are already seeing concrete results from our strategic investments. The Norwegian consumer market has developed strongly and has gone from low levels to today constituting a significant part of our e-commerce sales. This shows that our products and our business model have the potential to grow also in new markets. At the same time, partner sales remain uneven between quarters, as larger orders and deliveries occur periodically, which affects the short-term sales outcome.

We also view positively the upcoming warrants with an exercise period during the first half of June. If fully exercised, these could provide the company with a significant capital injection, which would further strengthen our financial position and enable increased investments in growth, product development and market expansion. We are also pleased with the ongoing strong support we have from our largest shareholder, which is an important statement of strength and a testament to the confidence in the company's strategy and future potential.

In parallel, work continues to ensure the right expertise and organization for the next phase of the company's development. Peptonic is now entering the next phase with a clearer strategic focus, improved financial conditions and an organization equipped for the future. We have implemented extensive change work and are today better positioned to create sustainable growth and long-term value for our shareholders.

We look to the future with great confidence and look forward to continuing our journey together with both existing and new investors.

Daniel Rudeklint,

Interim CEO

The interim report is available on the company's website: https://www.peptonicmedical.se/finansiell-information/

For further information, please contact:
Daniel Rudeklint, interim CEO Peptonic Medical AB

Email: daniel.rudeklint@peptonicmedical.se
Phone: +46 73 158 02 73

About Peptonic Medical AB                                

Peptonic Medical AB (publ) is a Swedish medical technology company that develops and sells clinically proven self-care products in intimate women's health. Under the brands VagiVital and Vernivia, the Company offers an over-the-counter portfolio of effective and gentle products that help women understand, treat and prevent common medical conditions in the genital area. Peptonic's growth strategy is based on geographic expansion, especially in the US and Europe, and on continuously strengthening the product portfolio through its own product development and strategic acquisitions.

The company is headquartered in Stockholm, Sweden, and has subsidiaries Peptonic Medical Inc. and Common Sense Marketing Inc. in the United States. Peptonic Medical was founded in 2009 and has been listed on the Spotlight Stock Market since 2014.